Paradigm in-licenses treatment for rare joint disease
Filed with ASX · · 3 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm receives $2.32m R&D tax incentive refund
- PAR reports pain reduction in 145 people with osteoarthritis
- Paradigm Agreement With USA Past Players Network
- Paradigms Updated Corporate Presentation
- Paradigm Raises A$9 Million
Later from Paradigm Biopharmaceuticals
- Paradigms AGM Presentation
- Paradigm reports consistent OA pain reduction
- PAR reports successful Phase 2 clinical trial
- Presentation of Phase 2 clinical trial results
- Paradigms supplementary Phase 2B data
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals